The cellular therapy from Israel’s Kadimastem (see here previously) was able to slow down the progression of ALS in its first human clinical trial on ten patients. Kadimastem’s Vice President of R&D Michal Izrael describes the treatment and the next trial.
ALS treatment trial success
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.